Blog & Resources Camargo Blog January 6th, 2011

2010 505(b)(2) Approvals

We join everyone else this time of year and develop a list – ours is a list of FDA approvals made under 505(b)(2). As widely reported (WSJ article here) FDA reported that approvals were down in 2010.

Frankly, it’s hard to tell what the figures are, let alone mean. The Agency sometimes includes approval of a biologic, but not all of them (with no explanation). The Agency also tries to separate 505(b)(1) and 505(b)(2) approvals but isn’t accurate. In 2010, as in past years, several approvals classified by the FDA as 505(b)(1) were based extensively on the literature. One division in particular seems to view all submissions as 505(b)(1)’s even when the majority of the data is based on public data.

So, as usual, when I develop my list of 505(b)(2) approvals I only list those drugs where the Agency specifically indicates that the approval was under 505(b)(2). Thus, in my list you will find a hyperlink with the approval date — this hyperlink jumps to the actual approval letter. Using this method, I am likely underreporting 505(b)(2) approvals.

Our tally is 22 505(b)(2) drug product approvals in 2010. According to the WSJ, 21 drug products were approved under 505(b)(1).

In 2010, there were no New Molecular Entities approved under 505(b)(2). Several NME’s were approved in 2008 and 2009. And, although there are several pro-drugs in development, none were approved in 2010.

As always, errors are mine. If you see one, please bring it to my attention.

Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.

Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.

9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights